The approvals of generic Sensipar (cinacalcet) for Indian firms Cipla and Aurobindo Pharma, while providing for the first generic competition for Sensipar, has turned the spotlight on Indian drug majors investing in the development of complex generics, reports The Pharma Letter’s India correspondent.